FULC Stock Falls as Muscle Disorder Study Misses Primary Goal - Illumina ( NASDAQ:ILMN ) , Fulcrum Therapeutics ( NASDAQ:FULC )
Shares of Fulcrum Therapeutics, Inc. FULC plunged 61.1% on Sept. 12 after the company announced disappointing top-line data from the phase III REACH study, which evaluated its pipeline candidate, losmapimod, for treating patients with facioscapulohumeral muscular dystrophy ( FSHD ) , a rare and ...
| Ticker |
Sentiment |
Impact |
|
ILMN
|
Somewhat Bullish
|
21 %
|
|
KRYS
|
Somewhat Bullish
|
28 %
|
|
FULC
|
Somewhat Bearish
|
21 %
|
